Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review.

摘要: Heart failure with reduced ejection fraction (HFrEF) is defined as the presence of typical symptoms heart (HF) and a left ventricular ≤ 40%. HFrEF patients constitute approximately 50% all clinical HF. Despite breakthrough discoveries advances in pharmacologic management HF, continue to pose significant economic burden due progressive disease characterized by recurrent hospitalizations need for advanced therapy. Although there are effective, guideline-directed medical therapies HFrEF, proportion these either not on appropriate medications' combination or optimal tolerable doses. Since morbidity mortality benefits some dose-dependent, therapy required impact disease, quality life, prognosis, curb health care expenditure. In this review, we summarize landmark trials that have impacted HF review contemporary HFrEF. We also provide insight general considerations specific populations. searched PubMed, Scopus, Medline Cochrane library relevant articles published until April 2019 using following key words "heart failure", "management", "treatment", "device therapy", "reduced fraction", "guidelines", "guideline directed "trials" itself combination. utilized cardiology portal identify related failure. reviewed guidelines, full articles, focused